• Molecular NameGatifloxacin
  • Synonymgatifloxacin
  • Weight375.4
  • Drugbank_IDDB01044
  • ACS_NO112811-59-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.01
  • pkaN/A
  • LogD (pH=7, predicted)-2.34
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.02
  • LogSw (predicted, AB/LogsW2.0)0.09
  • Sw (mg/ml) (predicted, ACD/Labs)0.34
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds4
  • TPSA82.11
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.
  • Absorption_value96.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability96.0
  • Protein binding20.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmGatifloxacin undergoes limited biotransformation in humans with less than 1% of the dose excreted in the urine as ethylenediamine and methylethylenediamine metabolites
  • Half lifeOral (discontinued), Intravenous (discontinued) ophthalmic
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A